Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II multicenter single arm non-randomized open label study of the
investigational drug, brentuximab vedotin, given in combination with routine chemotherapy
(rituximab, cyclophosphamide, doxorubicin and prednisone) every 3 weeks for a total of 6
cycles.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania